An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus.
An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus.
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
Inclusion Criteria:
Exclusion Criteria:
Witchita, Kansas, United States
Ciudad de Buenos Aires, Argentina
Salta - Salta, Argentina
Tasmania, Australia
North York, Ontario, Canada
Smith Falls, Ontario, Canada
Chomedey-Laval, Quebec, Canada
Monteccio Emilia, Italy
Toruñ, Poland
Belgrade, Serbia and Montenegro
Gauteng, South Africa
Berks, United Kingdom
Bucks, United Kingdom
Surrey, United Kingdom
Wiltshire, United Kingdom